模拟4因子前列红素复合物缩剂对XA因子相关出血的治疗效果
Ineke Muir1, Eva Herzog2, Markus Brechmann3
1CSL Innovations Pty Ltd, Victoria, Australia.
PloS one
|September 27, 2024
概括
四因子前激素复合缩物 (4F-PCC) 可以帮助恢复正常的血液凝固,在患有XA因子 (FXa) 抑制剂时出现出血的患者. 计算模型显示,4F-PCC有效地增加了血栓的生成,有助于血静.
科学领域:
- 血液学 血液学 血液学
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与Xa因子 (FXa) 抑制剂相关的出血的管理带来了重大的临床挑战.
- 大规模出血通常涉及复杂的凝血病,需要一种多模式的方法,而不仅仅是简单的FXa抑制剂逆转.
- 四因子前激素复合缩剂 (4F-PCC) 是一种已被认可的治疗FXa抑制剂相关出血的方法.
研究的目的:
- 通过计算探索4F-PCC对凝血级联的影响.
- 在模拟的FXa抑制剂治疗患者模型中研究血栓生成的恢复.
主要方法:
- 开发和应用一个修改的凝血级联计算模型.
- 模型校准和验证使用4F-PCC的维生素K对抗剂逆转的第三阶段临床试验数据.
- 模拟FXa抑制剂 (rivaroxaban,apixaban) 的作用和4F-PCC对血栓生成的干预.
主要成果:
- 在特定的校准条件下,经验证的模型预测了11.4秒的前热血素时间 (PT).
- 该模型成功模拟了里瓦罗克萨班和阿皮克萨班对总血栓度的影响.
- 模拟表明,4F-PCC的使用在里瓦罗克萨班或阿皮克萨班的存在下增加了血栓生成.
结论:
- 计算建模提供了关于4F-PCC在FXa抑制剂相关出血中的血静效应的见解.
- 4F-PCC有效增强血栓生成,支持其在管理复杂出血情景中的作用.
- 这项研究强调了 in silico 方法在评估抗凝剂逆转策略方面的潜力.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
636
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
01:30Venous Thrombosis IV: Nursing Management
3
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
3
01:20Extrinsic and Intrinsic Pathways of Hemostasis
6.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.3K
01:16Clot Retraction and Fibrinolysis
4.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.7K